Observed Apixaban Anti-Xa Levels in Obese Patients.

Weston HarknessOlivia PipitoneJacqueline JossMichael SchiedlerSanton ShagavahRyan MooreJeff Hsing

Published in: The Annals of pharmacotherapy (2022)

This study provides evidence that anti-Xa levels among obese patients are not substantially different from patients with nomral BMI and weight. This supports recent ISTH guidance for standard dosing of apixaban for VTE patients with BMI >40 kg/m2 or weight >120 kg and provides additional evidence that the standard dosing may also be appropriate in patients with AF.

Keyphrases

obese patients
bariatric surgery
body mass index
venous thromboembolism
weight loss
weight gain
atrial fibrillation
gastric bypass
roux en y gastric bypass
physical activity
body weight